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Abstract
Background: Lipoid proteinosis is a rare autosomal recessive disease characterized by cutaneous and mucosal
lesions and hoarseness appearing in early childhood. It is caused by homozygous or compound heterozygous
mutations in the ECM1 gene. The disease is largely uncharacterized in Arab population and the mutation(s)
spectrum in the Arab population is largely unknown. We report the neurologic and neuroradiologic characteristics
and ECM1 gene mutations of seven individuals with lipoid proteinosis (LP) from three unrelated consanguineous
families.
Methods: Clinical, neurologic, and neuro-ophthalmologic examinations; skin histopathology; brain CT and MRI; and
sequencing of the fullECM1 gene.
Results: All seven affected individuals had skin scarring and hoarseness from early childhood. The two children in
Family 1 had worse skin involvement and worse hoarseness than affected children of Families 2 and 3. Both
children in Family 1 were modestly mentally retarded, and one had typical calcifications of the amygdalae on CT
scan. Affected individuals in Families 2 and 3 had no grossneurologic, neurodevelopmental, or neuroimaging
abnormalities. Skin histopathology was compatible with LP in all three families. Sequencing the full coding region
of ECM1 gene revealed two novel mutationsin Family 1 (c.1300-1301delAA) and Family 2 (p.Cys269Tyr) and in
Family 3 a previously described 1163 bp deletion starting 34 bp into intron 8.
Conclusions: These individuals illustrate the neurologic spectrum of LP, including variable mental retardation,
personality changes, and mesial temporal calcificationand imply that significant neurologic involvement may be
somewhat less common than previously thought. The cause of neurologic abnormalities was not clear from either
neuroimaging or from what is known about ECM1 function. The severity of dermatologic abnormalities and
hoarseness generally correlated with neurologic abnormalities, with Family 1 being somewhat more affected in all
spheres than the other two families. Nevertheless, phenotype-genotype correlation was not obvious, possibly
because of difficulty quantifying the neurologic phenotype and because of genetic complexity.
Background
Lipoid proteinosis (LP; MIM 247100) is a rare autoso-
mal recessive disease characterized by cutaneous and
mucosal lesions and hoarseness appearing in early child-
hood [1] that is caused by homozygous or compound
heterozygous mutations in the ECM1 gene located on
chromosome 1q21 [2]. This gene encodes a protein that
is an important structural component of basement
membrane and extracellular matrix [3,4], and loss of
protein-protein interactions due to ECM1 gene muta-
tions is the likely cause of dermatologic abnormalities
including warty skin, scarring, and mucosal thickening
[5]. These changes also affect the nasopharynx, tongue,
and vocal cords, resulting in severe fibrosis and the
hoarseness characteristic of the disorder.
Approximately one third of affected individuals are
reported to have mild mental retardation [6], andneur-
opsychological problems may be more common [7-9].
Other reported neurologic abnormalities include com-
plex partial seizures, memory loss, and emotional diffi-
culties, often beginning in teenage years and progressing
from that time onward [6,8]. Calcification of the mesial
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progressive with age. Pathologic material is limited, and
the mechanism of brain injury remains uncertain.
We had the opportunity to study seven individuals
from three unrelated consanguineous families who had
the typical spectrum of skin, voice, and neurologicchar-
acteristics of LP with mutations in the ECM1 gene.
Methods
Seven participants from three unrelated Saudi Arabian
(Table 1) wereenrolled and all signed informed consent.
This study was approved by the institute IRB and
adhered to the tenets of the Declaration of Helsinki.
Blood samples were collected from all participants and
DNA was extracted and stored at -20°C until needed for
genetic testing.
Intelligence testing was performed by routine assessment
on neurologic examination and by using the Stanford Binet
Test (Patient II-1, Family 1) and the Wechsler Bellevue
Intelligence scale (Patient II-6, Family 1). Patients from
each family had skin punch biopsies including epidermis,
dermis, and subcutaneous tissue that were fixed in forma-
lin and stained with PAS and PAS/diastase. All affected
individualsexcept Patient II-6 of Family 2had brain com-
puted tomography (CT) and either 1.5 or 3.0 Tesla mag-
netic resonance imaging(MRI). MRI for patients from
Family 3 included Susceptibility-Weighted sequences.
The ECM1 gene was directly sequenced as described
previously in affected individuals, in available first
degree relatives, and in 100 chromosomes from healthy
individuals of matching ethnicity [2,3]. Nucleotide num-
bering for mutations reported in all three families was
referenced to the NCBI sequence (NG_012062).
Results
Direct sequencing of the ECM1 gene inthe two patients
(II-1 and II-6) from Family 1 (Figure 1a) identified a novel
homozygous two base deletion near the end of exon 8
(c.1300-1301delAA). The deletion occurred at codon 434
and was expected to create a premature stop codon two
codons later, likely to result in low levels of allECM1 tran-
scriptsand in severely truncated proteins [3].
Family 2 (Figure 1b) had a novel one-base substitution
mutation c.806G > Ain exon 7, which resulted in the
replacement of cystine with tyrosine at codon 269
(p.Cys269Tyr). This mutation was detected in homozy-
gous status in both patients (II-3 and II-6) and in hetero-
zygous status in both parents (I-1 and I-2) and one
unaffected siblings (II-4). An assessment of the patholo-
gic effect of this mutation utilizing PolyPhen, a tool
predicting the possible impact of an amino acid substitu-
tion on the structure and function of a human protein
using physical and comparative considerations http://
genetics.bwh.harvard.edu/pph/ [10], predicted this muta-
tion to be probably damaging (i.e., very likely to affect
protein structure and/or function). Exon 7 is represented
in transcripts ECM1a and ECM1c [11]but not in the
ECM1b transcript, and therefore, presumably the ECM1b
transcript would be normal in this family.
Table 1 Demographics of three families
Sub ID Family Sex Age at last exam
II-1 1 M 24 years
II-6 1 F 14 years
II-3 2 F 19 years
II-6 2 F 12 years
II-1 3 F 18 years
II-2 3 M 12 years
II-3 3 M 5 years
Figure 1 Pedigrees and Genetic Results.( a )F a m i l y1p e d i g r e e
and ECM1 chromatogram showing a homozygous two base
deletion detected in affected family members. b) Family 2 pedigree
and ECM1 chromatogram showing a homozygous base substitution
in both affected individuals (II-3 and II-6) and heterozygous base
substitution in their mother. Similar heterozygous results were also
found in father (II-1) and an unaffected sibling (II-4) but are not
shown. c) Family 3 pedigree with photograph of a 1.5% agarose gel
showing failed amplification of exons 9 and 10 in all affected
individuals but not in their mother or unaffected brother. Forward
primer was designed in intron 8 and the reverse primer was
designed in intron 10.
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Page 2 of 6Family 3 (Figure 1c) had a 1163 bp deletion starting
34 bp into intron 8 and encompassing all of exon-9,
intron-9, and exon 10, including the termination codon
and part of the 3’-UTR. This mutation was detected in
homozygous status in all affected individuals in this
family (II-1, II-2, II-3), but was not present in an unaf-
fected sibling (II-4). The mother was a carrier of the
mutation; the father was deceased but was also expected
to be a carrier. This mutation was previously reported
in an affected Saudi family from the same tribe thatmay
be related by founder effect to the current family [2]. It
results in complete loss of exons 9 and 10 from tran-
scripts ECM1a/c and ECM1b and is predicted to have a
deleterious effect on protein structure and function [2].
The two siblings in Family 1 were the only affected
individuals in this consanguineous family with seven
children (Figure 1A). Patient II-1 was born at eight
months gestation and stayed in a neonatal intensive care
unit for six weeks, while Patient II-6 was the product of
a normal pregnancy and delivery. They each had mild
motor delay, walking at age 18 months and talking at
a p p r o x i m a t e l ya g et h r e ey e a r s .T h e yw e r em o d e s t l y
mentally retarded with intelligence quotients of approxi-
mately 60 and a requirement for special education.
Neither had developed seizures or obvious emotional
problems when last examined at ages 25 (Patient II-1)
and 14 (Patient II-6)years.
Both children had normal skin appearance at birth,
but each had an abnormal cry and developed hoarseness
by age six months. Patient II-1 had the most severe pre-
sentation during early childhood in this group with irre-
gular, indurated, partially coalescent yellowish papules
with hypo- and hyperpigmented macular plaques in the
lower back and gluteal regions. He developed skin-
colored, verrucous papules and nodules on the elbows,
knees, and sites of friction and movement including the
hands. His tongue was enlarged and woody, hard on
palpation, with inability to protrude tongue. The frenu-
lum and oral mucosa were infiltrated, but dentition was
normal. Laryngoscopy revealed hypertrophic vocal cords
with normal movement. Patient II-6 had a milder pre-
sentation in early childhood with mildly itchy, erythema-
tous maculopapular skin eruptions over both extremities
that developed gradually into hyperpigmented, verrucous
areas over elbows, knees, and knuckles. Both had small-
hands and digits. They had mild microcephaly with a
saddle nose and eyelid thickening (moniliform blepharo-
sis). Muscle mass and strength were normal, but both
had mild lower extremity spasticity with modest asym-
metric hyperreflexia but without dystonic changes. Gait
was grossly normal.
Skin biopsies revealed extensive deposition of amor-
phous eosinophilic, hyaline material characteristic of LP
consisting of thick, homogenous bundles extending
perpendicular to the skin surface. These bundles sur-
rounded blood vessels in the thickened papillary dermis,
and this material was PAS positive and diastase resistant
(Figure 2). There were no ischemic changes around
blood vessels.
Brain computed tomography (CT) of Patient II-6 at
age 10 years showed small calcifications in the amygdala
bilaterally (Figure 3a). CT and magnetic resonance ima-
ging (MRI) scans were otherwise normal with no evi-
dence of atrophy or ischemia (Figure 3b). CT of Patient
II-1revealed no brain calcification; however, both CT
and MRI showed a watershed ischemic injury involving
the right cerebral hemisphere with periventricular white
matter loss (Figure 3c) and thickening of the overlying
skull implying chronicity. He also had atrophy of the
right cerebellar hemisphere and middle cerebellar ped-
uncle (Figure 3d).
In general, patients from Family 2 (Figure 1b) were
slightly more affected than patients from Family 3
(Figure 1c), although both families were less affected
than Family 1. Rough, yellowish-white papular deposits
in the skin and the oral mucosa were presentwithin the
first year of life. They all developed multiple, small,
severe blisters over the fingers of both hands leading to
excoriations and post inflammatory hyperpigmentation
mainly over joints with mild facial skin changes but no
striking scarring. They all had beaded papules on the
upper and lower labial mucosa and tongue together
with multiple, small, waxy, yellow beaded papules along
the eyelids (moniliform blepharosis). Hoarseness and
pharyngeal involvement were present but also less
evident.
Individuals from Families 2 and 3 had no developmen-
tal delay, and head circumference was normal in each.
They were not mentally retarded, and each attended
Figure 2 Papillary dermis. (a) Deposition of PAS positive and
diastase-resistant material from Patient II-1 of Family 1. Rare
inflammatory cells are seen in the upper dermis (original
magnification X 200). (b) PAS positive material deposited around
blood vessels which have thickened and hyalinized walls. (arrows,
original magnification X 400). There was no evidence of infarction.
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youngest, who was not yet in school, and the girl from
Family 3 (II-3), who dropped out of school, possibly for
emotional reasons. Basic neurologic examinations were
normal with no reflex or gait abnormality. CT and MRI
scans (including Susceptibility-Weighted sequences,
which are particularly sensitive to calcification and iron
deposition) in each affected individual, except for
Patient II-6 of Family 2, showed no temporal lobe calci-
fication and no other brain abnormalities.
Discussion
These seven patients alldeveloped characteristic skin
lesions and hoarseness in infancy and had unequivocal
LP by skin biopsy. Two individuals from Family 1 had
modest mental retardation, and one had small amygdala
calcifications, but the other affected patients had no
definitive neurologic involvement when last examined
between ages five and 19 years. All seven individuals
had homozygous mutations in the ECM1 gene [3,12,13];
Families 1 and 2 had novel ECM1 mutations, while
Family 3 had a previously reported large deletion [2].
Innate severity of LP phenotypic expression is difficult
to gauge for a number of reasons, even in carefully evalu-
ated patients. Skin manifestations are recognized to be
variable within families and even from time to time
within the same individual, generally increasing with age
and skin exposure, which is often determined by environ-
ment and employment. Pharyngeal involvement is usually
obvious because of hoarseness and fibrosis involving the
tongue and pharyngeal tissue, but these changes are diffi-
cult to quantify. Overt mental retardation may be
straightforward to recognize, as in two of our patients,
but more subtle intelligence changesmay not be easy to
detect and may not be reported by families wishing to
minimize their own impression of the impact of this
genetic disease. Detecting subtle emotional or personality
changes requires formal, quantitative neuropsychological
testing standardized to the appropriate language and eth-
nic group. Such testing is not often available, as in the
case of the families reported here. These families also
demonstrate that current quality brain CT and MRI may
be entirely normal in the temporal lobes and elsewhere
even in teenage years and even with some indication of
emotional difficulties (e.g., Patient II-3of Family 3).
LP has been reported to cause a variety of neurologic
problems, including psychosis [9], partial complex sei-
zures [6], emotional incontinence including rage and
panic attacks [14], and progressive memory loss [7],
most commonly of memories with emotional content
[8]. Mental retardation has been reported in approxi-
mately one third of individuals with LP [6,9,15] and was
documented in two of these seven individuals. The rela-
tive infrequency of other obviousneurologic abnormal-
ities may be due tochance in a small series of patients
or to the subtlety of changes in cognitive function or
personality. Alternatively, patients with advanced or
obvious neurologic abnormalities may have been over-
represented in classic reports, or neuropsychological
changes may be more frequent in certain well-studied
populations (e.g., South African) than in others [16].
The etiology of mental retardation in LP remains
uncertain because currently there is no information
about ECM1 expression in human brain outside of
blood vessels [12]. The ECM1 gene is an integral part of
the extracellular matrix and basement membrane struc-
ture. These roles likely lead directly to the classic skin
and pharyngeal damage when ECM1 is mutated [3], but
the relevance to brain is less obvious. ECM1 interacts
with other proteins making up the extracellular matrix
[17,18], often regulating bioactivity of the binding
Figure 3 Brain CT and MRI of Patients 1 and 2. (a) Brain CT
image of Patient II-6 of Family 1 at age of 10 years showing a small
calcification in the left amygdale. Calcification in the right amygdale
was seen on another section (not shown). (b) Brain axial T2-
weighted MR image of the same patientat the level of temporal
lobes showing a tiny hypointensity (arrow) representing amygdala
calcification. The mesial temporal lobes were otherwise normal.
(c) Brain axial T2-weighted MR images of Patient II-1 of Family 1
showing enlarged sulci and small gyri in the watershed zones of
the right frontal lobe (open arrows) associated with loss of white
matter due to old ischemia. (d) The right cerebellar hemisphere of
the same patientwas small with widened folia, white matter gliosis
(arrow), and a small right middle cerebellar peduncle (asterisk).
Remodeling of the posterior fossa confirmed the long-standing
nature of this abnormality. CT and MRI scans on patients from
Families 2 and 3 were normal.
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Page 4 of 6partner [11], includingmatrix metalloproteinase 9 [19],
which has an important role in temporal lobe synaptic
physiology [20]. ECM1 mutations, therefore, might affect
brain function, compromise homeostasis, or impair
repair mechanisms independent of ischemia [19,21].
The brain pathophysiology of ECM1 has been
hypothesized to result from a defect in cerebrovascular
basement membrane that causes fibrinoid changes and
calcification of vessel walls [8,15,22]. However, available
neuropathology is limited, is from older individuals, and
leaves open the question of whether the vascular pathol-
ogy described is primary or secondary to some other
process. Careful review of CT and MRI images yielded
no hint of brain damage, including in the area immedi-
ately contiguous to temporal lobe calcification [14] in
previously reported patients [4,8,14,23] or in Patient II-6
of Family 1. Therefore, a cerebral vasculopathic mechan-
ism is not supported by the absence of ischemic changes
on CT or MRI neuroimaging or in skin biopsies [6].
Even if ischemia were the cause of temporal lobe calcifi-
cation, it is still unclear why this process should affect a
particular area of the mesial temporal lobe and, when
advanced, cause a fairly consistent comma-shaped area
of calcification [24].
Patients from Family 1 were more affected in terms of
skin, pharyngeal, and neurologic involvement than patients
from Families 2 and 3, suggesting that severity ofintegu-
mentinvolvement may roughly correspond to severity of
brain involvement in certain LP individuals and families.
Hamada and colleagues noted that individuals with muta-
tions outside of exon 7 seemed more affected than indivi-
duals with mutations involving exon 7 of the ECM1 gene
[3]. Indeed, Family 1, with a mutation in exon 8, was more
affected than Family 2, with a mutation in exon 7. How-
ever, Family 1 had a two nucleotide deletion at the end of
exon 8, leading almost immediately to a premature stop
codon and effectively truncating all transcripts at that
point. Family 3 had a large deletion removing exons 9 and
10 and accomplishing a comparable genetic defect. Never-
theless, skin, pharynx, and nervous systemof Family 1 see-
medmore affected than in Family 3.
Most genetic reports regarding LP have observed that
phenotype-genotype correlations are not obvious [3,25],
and this seems also to be true in our three families. The
ECM1 gene has several transcripts, each of which may
be differentially active in various tissues, including var-
ious parts of the brain, at different times during an indi-
vidual’s lifetime, offering the possibility of substantial
variability in the effect of mutations in particular indivi-
duals. In addition, novel transcripts may provide partial
rescue through in-frame skipping of mutated exons in
certain circumstances [3]. This genetic complexity is
currently difficult to either predict or assess in indivi-
dual patients. Similarly, our current ability to completely
quantify clinical, including neurologic, involvement is
limited. Taken together, these factors mean that the lack
of phenotype-genotype correlation is not surprising.
Therefore, a suspected diagnosis of LP should be con-
firmed by sequencing ECM1 exons 6 and 7 first because
this is where most mutations occur [3], but homozygous
or compound heterozygous mutations of any type may
occur in any exon.
Conclusions
These individuals illustrate the neurologic spectrum of
LP, including variable mental retardation, personality
changes, and mesial temporal calcification but imply
that significant neurologic involvement may be some-
what less common that previously thought. The cause
of neurologic abnormalities was not clear from either
neuroimaging or from what is known about ECM1 func-
tion. The severity of dermatologic abnormalities and
hoarseness generally correlated with neurologic abnorm-
alities, with Family 1 being somewhat more affected in
all spheres than the other two families. Nevertheless,
phenotype-genotype correlation was not obvious, possi-
bly because of difficulty quantifying the neurologic phe-
notype and because of genetic complexity.
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